Abstract
Pharmaceutical companies are responsible for respecting human rights to health in the fight against COVID-19. In this context, due diligence would require pharmaceutical companies to realistically assess their capabilities when making pricing and distribution decisions in order to maximize human access to their products. During the pandemic, companies' actions in the direction of pricing and distribution of products deviated from the goals set by the WHO Charter and the UN 2030 Agenda, acting in order to maximize their profits.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
